Grail will not submit a new FDA regulatory filing or announce a new clinical trial partnership by October 16, 2026.
Posted 2026-10-02 — 14 days before the deadline, stated before the outcome.
The claim
Grail will not submit a new FDA regulatory filing or announce a new clinical trial partnership by October 16, 2026.
Reasoning trace
- The current signals provided are entirely unrelated to Grail (focusing on Amazon, Dell, Marvell, Intel, NVIDIA, and Synopsys).
- Grail recently presented PATHFINDER 2 results at ASCO 2026, which is a major data release that typically precedes a period of analysis rather than immediate subsequent filings.
- The surge in coverage (z=4.9) may be algorithmic noise or retrospective analysis of the ASCO data rather than news of a new pending event.
Evidence so far
0 confirming · 0 denying signals · 0 verified · 1 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 2 times since mint (last on 2026-10-02) — 78% at mint → 84% today.
What to watch
- leading indicator Grail announces a new clinical trial partnership or collaboration agreement in a public press release
- milestone Grail or a partner submits a ClinicalTrials.gov registration for a new multi-center or collaborative trial
- leading indicator A named academic or hospital partner publicly confirms a data-sharing or research agreement with Grail
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.